Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review
Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review
复制标题
DOI：
10.1016/s0753-3322(00)89027-7
复制
发表时间：
2000-05-01
影响因子：
7.5
通讯作者：
Poland, GA
中科院分区：
文献类型：
--
作者：
Boyce, TG;Poland, GA
尽管有灭活流感疫苗，流感仍然造成老年人相当大的死亡率和所有年龄段的发病率。冷适应、减毒活、鼻内注射流感疫苗于 20 世纪 60 年代首次开发，已在 10,000 多名志愿者中进行了测试，并被证明是安全的、耐受性良好且具有免疫原性。最近的试验表明，对儿童的功效可能优于灭活疫苗，对健康成人的功效可能与灭活疫苗相似，尽管直接比较两种疫苗的数据有限。减毒活疫苗的优点包括可接受性、易于施用以及大规模免疫的潜力。所有年龄段的疫苗接种率都可能大幅提高，这为群体免疫的发展带来了希望，并大大改善了未来对流感的控制。 (C) 2000 年科学与医学版 Elsevier SAS。
Despite the availability of inactivated influenza vaccines, influenza continues to cause considerable mortality in the elderly, and morbidity in all age groups. Cold-adapted, live-attenuated, intranasally administered influenza vaccines, first developed in the 1960s, have been tested in more than 10,000 volunteers and have been shown to be safe, well-tolerated, and immunogenic. Recent trials suggest that efficacy in children may be superior to that of inactivated vaccines, and efficacy in healthy adults may be similar to that of inactivated vaccines, although there are limited data comparing the two vaccines directly. Advantages of the live attenuated vaccines include acceptability, ease of administration, and the potential for mass immunization. The possibility of substantially higher vaccination rates across all age groups brings promise for the development of herd immunity and greatly improved control of influenza in the future. (C) 2000 Editions scientifiques et medicales Elsevier SAS.